News | January 18, 2023
Heart failure treatment becomes affordable with Glenmark launching Sacubitril + Valsartan tablets
Sacu V is priced at Rs. 19 per tablet for a dose of 50 mg (sacubitril 24 mg + valsartan 26 mg)
Sacu V is priced at Rs. 19 per tablet for a dose of 50 mg (sacubitril 24 mg + valsartan 26 mg)
The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”
Partnership to leverage the Helix Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise
Modi stressed the need to ensure that the entire Covid infrastructure at all levels is maintained at a high level of preparedness in terms of equipment, processes, and human resources
This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
The product is backed by required scientific proof and comparative bioequivalence studies
Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
The receipt of this permission paves way for the launch of Dapagliflozin (Forxiga) tablets of 10 mg in India for the specified additional/expanded indication, subject to the receipt of related statutory approvals
India is home to nearly 80 million diabetics and this number is expected to rise to a staggering 134 million in the next 25 years.
Subscribe To Our Newsletter & Stay Updated
